Evidence map›Paper›PMID 33731156›Full record

ArticleJournal of neuroinflammation2021

Pharmacological ablation of astrocytes reduces Aβ degradation and synaptic connectivity in an ex vivo model of Alzheimer's disease.

Nicola Davis, Bibiana C Mota, Larissa Stead, Emily O C Palmer, Laura Lombardero, Rafael Rodríguez-Puertas, Vincenzo de Paola, Samuel J Barnes, Magdalena Sastre

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Midbrain PAG Astrocytes Modulate Mouse Defensive and Panic-Like Behaviors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Review
  5. Biochemistry and biophysics reports · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Role of NRF2 in Pathogenesis of Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Nicola DavisDepartment of Brain Sciences, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.
Bibiana C MotaDepartment of Brain Sciences, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.
Larissa SteadDepartment of Brain Sciences, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.
Emily O C PalmerDepartment of Brain Sciences, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.
Laura LombarderoDepartment of Pharmacology, University of the Basque Country (UPV/EHU), 48940, Leioa, Spain.
Rafael Rodríguez-PuertasDepartment of Pharmacology, University of the Basque Country (UPV/EHU), 48940, Leioa, Spain.
Vincenzo de PaolaInstitute of Clinical Sciences, Imperial College London, London, W12 0NN, UK.
Samuel J BarnesDepartment of Brain Sciences, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.
Magdalena SastreDepartment of Brain Sciences, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK. m.sastre@imperial.ac.uk.ORCID http://orcid.org/0000-0001-8931-6316
Hammersmith Hospital · GBUniversity of the Basque Country · ESImperial College London · GB

Funding

Medical Research Council MR/P006434/1
6 · The paper itself

Abstract

backgroundAstrocytes provide a vital support to neurons in normal and pathological conditions. In Alzheimer's disease (AD) brains, reactive astrocytes have been found surrounding amyloid plaques, forming an astrocytic scar. However, their role and potential mechanisms whereby they affect neuroinflammation, amyloid pathology, and synaptic density in AD remain unclear.

methodsTo explore the role of astrocytes on Aβ pathology and neuroinflammatory markers, we pharmacologically ablated them in organotypic brain culture slices (OBCSs) from 5XFAD mouse model of AD and wild-type (WT) littermates with the selective astrocytic toxin L-alpha-aminoadipate (L-AAA). To examine the effects on synaptic circuitry, we measured dendritic spine number and size in OBCSs from Thy-1-GFP transgenic mice incubated with synthetic Aβ42 or double transgenics Thy-1-GFP/5XFAD mice treated with LAAA or vehicle for 24 h.

resultsTreatment of OBCSs with L-AAA resulted in an increased expression of pro-inflammatory cytokine IL-6 in conditioned media of WTs and 5XFAD slices, associated with changes in microglia morphology but not in density. The profile of inflammatory markers following astrocytic loss was different in WT and transgenic cultures, showing reductions in inflammatory mediators produced in astrocytes only in WT sections. In addition, pharmacological ablation of astrocytes led to an increase in Aβ levels in homogenates of OBCS from 5XFAD mice compared with vehicle controls, with reduced enzymatic degradation of Aβ due to lower neprilysin and insulin-degrading enzyme (IDE) expression. Furthermore, OBSCs from wild-type mice treated with L-AAA and synthetic amyloid presented 56% higher levels of Aβ in culture media compared to sections treated with Aβ alone, concomitant with reduced expression of IDE in culture medium, suggesting that astrocytes contribute to Aβ clearance and degradation. Quantification of hippocampal dendritic spines revealed a reduction in their density following L-AAA treatment in all groups analyzed. In addition, pharmacological ablation of astrocytes resulted in a decrease in spine size in 5XFAD OBCSs but not in OBCSs from WT treated with synthetic Aβ compared to vehicle control.

conclusionsAstrocytes play a protective role in AD by aiding Aβ clearance and supporting synaptic plasticity.

Indexed as

2-Aminoadipic AcidAlzheimer DiseaseAmyloid beta-PeptidesAnimalsAstrocytesCell SizeDendritic SpinesEncephalitisHumansInterleukin-6MiceMice, TransgenicNeural PathwaysPeptide FragmentsSynapses2-Aminoadipic AcidAmyloid beta-Peptidesamyloid beta-protein (1-42)Interleukin-6interleukin-6, mousePeptide FragmentsAmyloid-βAstrocytesCytokinesL-AAAOrganotypic culturesSynapsis

Identifiers

PMID33731156
PMCPMC7972219
OpenAlexW3113481963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.